PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment

Phospholipase A2 (PLA2) designates a large and diverse

group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Sediments a likely culprit in spread of deadly disease on Florida coral reefs

New findings also point to coastal construction as potential way of further spreading coral disease. A new study found that seafloor sediments have the potential to transmit a deadly pathogen…

How a smart electric grid will power our future

Reimagining the United States power grid could save consumers $50 billion a year. A novel plan that offers partnership in keeping the United States electric grid stable and reliable could…

Worldwide assessment of protected areas

Protected areas are among the most effective tools for preserving biodiversity. However, new protected areas are often created without considering existing ones. This can lead to an overrepresentation of the…

Partners & Sponsors